Pharmaceutical Competitive Intelligence

Close Icon We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By continuing to use the website, you consent to our use of cookies.

Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC

This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Products:

Conferences 2021

Awards

Upcoming Webinars

Webinar recordings

Close Icon

Global Search Configuration

Search Site Products & Services
Close Icon

Search by Keyword

Focus
Needs

Master the marketplace

To succeed in the pharmaceutical marketplace, it’s vital to stay up to date with developments that can affect your business. Our competitive and market intelligence can give you all the credible, detailed information you need in one place.

What we offer

You can quickly access referenced information across global key industry developments in the pharmaceutical and medical technology markets with our easy-to-use solutions and expert analysts.

Build detailed competitive and market landscape analyses quickly, with access to global information on:

Drug and device development
Patient populations
Clinical trials
Drug and device patents
Market moving events
Patient-based sales forecasts

How it helps

We help you more accurately:

Prioritize pharmaceutical R&D spend by finding gaps and unmet needs through the analysis of competitors’ targets and R&D priorities
Understand disease epidemiology and disease sub-populations targeted in clinical development
Anticipate market changes through patent expiration tracking
Earmark who is entering or exiting your market via licensing or acquisition, as well as who is securing or providing funding
Project revenue for your pipeline and marketed drugs

Relevant products

Discover the power of Pharma360

Datamonitor Healthcare: data analysis and insight

Datamonitor Healthcare's expert coverage of key diseases, companies, drugs and market trends makes it the go-to product for pharmaceutical and biotechnology companies to support the development and validation of their strategic plans and commercial decisions.

Key benefits:

Prioritize market opportunities
Identify unmet needs
Make informed decisions

Biomedtracker: see the drug development process through analysts’ eyes

Real-time tracking and analysis of the drug development pipeline

Key benefits:

Market Events & Catalysts
Likelihood of Approval
Deals Coverage

View all content

Biomedtracker, Meddevicetracker

Q3 2021 Outlook Report

27 Aug 2021

What major drug catalysts and events can you expect to see in the months ahead? Download your free extract from the Q3 2021 Outlook Report and infographic to find out. Shape your strategy with your inside look at what’s to come.

Topic Drug Review

Single report
Scrip

Chinese Biotechs Join COVID-19 Treatment Race With Repurposed Cancer Drugs

By Dexter Yan 18 Aug 2021

Chinese bioventures leap into the COVID cure fray as two little-known companies kick off clinical studies of androgen receptor antagonists in Brazil and the US.

View article
Scrip

Quick Listen: Scrip’s Five Must-Know Things

By Ian Haydock 16 Aug 2021

In this week's podcast edition of Five Must-Know Things: a history of Alzheimer’s drug development; BioNTech looks beyond COVID-19 vaccines; gene therapy setbacks for bluebird; new promise for Roche’s Polivy in B-cell lymphoma; and rising US momentum for US drug price negotiations.

View article
Datamonitor Healthcare, Biomedtracker, Scrip

2021 Post-ASCO Insights and Analysis

11 Aug 2021

The American Society of Clinical Oncology (ASCO) hosted its annual meeting from June 4-8 2021 and our team has the exclusive insights and analysis you can access today.

Topic Cancer

Single report
Scrip

Alzheimer’s Disease: Many Failures Before One Success

By Mandy Jackson 10 Aug 2021

For Biogen/Eisai’s success with Aduhelm, there were 93 failures in the anti-amyloid field. Scrip took a look back at how the pipeline for amyloid-targeting Alzheimer’s drugs progressed over roughly the past decade to showcase exactly how difficult the Alzheimer’s space has been.

View article
Scrip

Oncology, Cell Therapy Developers Bag $175m In China

By Dexter Yan 10 Aug 2021

Investors continue to focus on anticancer therapies including small molecule drugs and cell therapies in China.

View article
Scrip

Quick Listen: Scrip’s Five Must-Know Things

By Ian Haydock 09 Aug 2021

In this week's podcast edition of Five Must-Know Things: AstraZeneca looks to return to normality; Bayer’s hopes for Kerendia; Novartis’s plans for a new version of Zolgensma; Arcturus benefits from mRNA interest; and AbbVie changes tack in Alzheimer’s.

View article
Scrip

Novavax Pins COVID-19 Hopes On Ex-US, Booster Markets

By Alaric DeArment 06 Aug 2021

The company is planning to file with regulators in the UK, EU, Canada, Australia and New Zealand, with an emphasis on booster shots in developed markets.

View article
Scrip

Canadian Biotech Takes COVID-19 Nasal Spray To Asia Via Glenmark

By Anju Ghangurde 03 Aug 2021

Glenmark hopes to launch SaNOtize’s nitric oxide nasal spray for COVID-19 in India by the fourth quarter of 2021 post Phase III trials, as part of wider deal that covers other Asian markets. Can the self-administered product impact market dynamics positioned as the first line of defense against COVID-19?

View article
Scrip

Back To The Day Job? AstraZeneca’s Pangalos Looks Ahead To A Post-Pandemic Pipeline

By Andrew McConaghie 03 Aug 2021

Has AstraZeneca been able to maintain its R&D productivity, even during a pandemic, and with the huge task of delivering a not-for-profit COVID-19 vaccine to the world?AstraZeneca’s Mene Pangalos believes the company has not missed a beat, and can find new energy from finally working together in its new R&D headquarters.

View article
Scrip

Quick Listen: Scrip’s Five Must-Know Things

By Ian Haydock 25 Jul 2021

In this week's podcast edition of Five Must-Know Things: J&J’s outlook for coronavirus vaccines; Cosentyx comes in strong for Novartis; Biogen’s views on Aduhelm pricing; competition in the “dustat” sector; and dealing with endemic COVID-19.

View article
Scrip

Where To Start Tackling ‘Long Covid’? PureTech Pioneers Lung Drug Trial

By Andrew McConaghie 22 Jul 2021

PureTech is among the very first companies to attempt to treat long Covid and hopes its anti-fibrosis drug can aid patients’ recovery

View article
Scrip

Novartis Bounces Back From COVID-19 And Cosentyx Keeps Climbing

By Kevin Grogan 21 Jul 2021

Sales at the Swiss major have returned to around 80%-90% of their pre-pandemic levels, according to CFO Harry Kirsch after unveiling a healthy set of second-quarter financials.

View article
Scrip

Claims Stream In Under COVAX No-Fault Compensation Program

By Anju Ghangurde 07 Jul 2021

The WHO indicates that several claim applications have been made under the COVAX no-fault lump-sum compensation program for COVID-19 vaccines. It remains to be seen how the scheme may apply to countries like India, which is also expected to take a call on indemnity to vaccine makers.

View article
Pharma 360

Global Oncology Opportunities & Trends 2025: Key Markets, Indications and Products

06 Jul 2021

Join Informa Pharma Intelligence for the “Global Oncology Opportunities” webinar!

View article